Allogene Therapeutics, Inc. - Common Stock (ALLO)

Allogene Therapeutics is a biotechnology company focused on developing innovative cancer immunotherapies using engineered allogeneic T cells

The company's proprietary platform leverages cutting-edge gene-editing technologies to create off-the-shelf treatments that can be administered to multiple patients, aiming to enhance the body’s immune response against cancer. Through extensive research and clinical trials, Allogene is working to provide effective and accessible options for individuals suffering from various hematologic malignancies and solid tumors, promoting advancements in the field of cell therapy.